SIRT3 and non-small cell lung carcinoma: Consistent with our previous findings [12], inhibition via Sirt-3 mRNA expression (Figure 3D and 3F; p < 0.05, NCI-H460) or SIRT-3 enzyme activity (Figure 3E and 3F; p < 0.05, A549/NCI-H460) significantly inhibited TL-induced CAV-1 protein down-regulation following TL treatment, indicating SIRT-3 appears necessary for TL/CAV-1 pathway in both NSCLC cells.